Boehringer Ingelheim

#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use.

Learn more: go.boehringer.com/VHCH-

#LifeForward

#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.

Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.

Read more 👉 go.boehringer.com/VecpO
#LifeForward

Partnering to drive innovation

#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease

This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm

Hi, so sorry to hear that. Could you kindly let us know which website you're referring to? We'll look into this accordingly. Kind regards, Helen

#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.

Learn more here: go.boehringer.com/SYRTX

#LifeForward #PulmonaryFibrosis

Understanding and treating HER2driven lung cancer is a critical need.

In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research.

Learn more here: LCRF.org/251209bi

Researcher and winner of the Heinrich Wieland Prize Dr. Adrian Krainer is smiling into the camera. There is a quote saying "It warms my heart to see our research turn into a drug that saves lives."

Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T
#medsky #pharmsky

#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪

In a field where milestones are scarce, today signals meaningful momentum for the PPF community.

Learn more: go.boehringer.com/ao0kp

#LifeForward

#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA.

Find out more here go.boehringer.com/Fyr8N

#LifeForward #Oncology

#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl

Boehringer acquires new pre-clinical program targeting autoimmune diseases.

#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪

Learn more: go.boehringer.com/MPRF

#Innovation #AutoimmuneDiseases #PharmSky

#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF).

🧪 Learn more here: go.boehringer.com/HdX1

The immune system has the remarkable ability to identify and eliminate cancer cells.

Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.

Learn more 🧪: go.boehringer.com/Ki82v

#LifeForward #Oncology

#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.

These advancements have the potential to fulfill patients’ unmet needs.

🧪 Find out more: go.boehringer.com/FU9K9

#LifeForward #Oncology

Living with cancer, the small, positive moments often have the biggest impact.

We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.

🧪 Discover how these moments make a difference: go.boehringer.com/YomJY

#LifeForward #Oncology

#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.

🧪 Learn more: go.boehringer.com/GCZ1

#LifeForward #Oncology

#NEWS:  The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪

Learn more here: go.boehringer.com/rtx-w

#LifeForward

#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪

 #ERS2025 #LifeForward

#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪

Find out more here: go.boehringer.com/dz4O

#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪

Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL

We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪

Learn more: go.boehringer.com/HP-j5

#LungHealth #IPF

#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪

Learn more here: go.boehringer.com/YrIQ

#LifeForward #Oncology

A male researcher working in a lab

#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪

Learn more: go.boehringer.com/py5Iu

#EyeHealth #DiabeticRetinopathy #Innovation

At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).

With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.

#LifeForward #Oncology #Medsky

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov‬.

Learn more here 👉: www.boehringer-ingelheim.com/human-health...

#LifeForward #Oncology

#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF

H1 Results of Boehringer Ingelheim: Growth and pipeline progress

#NEWS: First Half of 2025

👉 EUR 14.0 billion in group net sales

👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch

👉 #AnimalHealth business grew by 7.6%

👉 Fast-growing pipeline in cardio-renal-metabolic diseases

Learn more ➡️ go.boehringer.com/w7ce3

#NEWS: We’re kicking off a new chapter in digital health through our collaboration with Eko Health to improve heart murmur detection in dogs. We will bring an AI-powered tool to veterinarians to give dogs and pet owners more years of life to love. 🐕 #LifeForward

Learn more: go.boehringer.com/4olwa

#NEWS: Tackling cardiovascular, renal and metabolic conditions together may be the key to hitting the UN’s 2030 goal of cutting early deaths from #NCDs by a third.

Explore how 16 countries are tackling these challenges in the global Future Health report, launched at #WHA78.
👉 bit.ly/4jeQ6WZ

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l

#LifeForward